Jeffrey I. Zwicker

Jeffrey I. Zwicker

Auto-generated profile, based on publicly available information

Jeffrey I. Zwicker

Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in Blood
Verified
Journal Article
Open access
PDF file
AVAbi Vijenthira
Abi Vijenthira
IGInna Y. Gong
Inna Y. Gong
TFThomas A. Fox
Thomas A. Fox
SBStephen Booth
Stephen Booth
GCGordon Cook
Gordon Cook
LHLisa K. Hicks
Lisa K. Hicks
Outcomes for patients with hematologic malignancy infected with COVID-19 have not been aggregated. The objective of this study was to perform a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. We searched PubMed and EMBASE up to 20 August 2020 to identify reports of patients with hematologic malignancy and COVID-19. The primary outcome was a pooled mortality estimate, considering all patients and only hospitalized patients. Secondary outcomes included risk of intensive care unit admission and ventilation in hospitalized patients. Subgroup analyses included mortality stratified by age, treatment status, and malignancy subtype. Pooled prevalence, risk ratios (RRs), and 95% confidence intervals (CIs) were calculated using a random-effects model. Thirty-four adult and 5 pediatric studies (3377 patients) from Asia, Europe, and North America were included (14 of 34 adult studies included only hospitalized patients). Risk of death among adult patients was 34% (95% CI, 28-39; N = 3240) in this sample of predominantly hospitalized patients. Patients aged ≥60 years had a significantly higher risk of death than patients <60 years (RR, 1.82; 95% CI, 1.45-2.27; N = 1169). The risk of death in pediatric patients was 4% (95% CI, 1-9; N = 102). RR of death comparing patients with recent systemic anticancer therapy to no treatment was 1.17 (95% CI, 0.83-1.64; N = 736). Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying. Patients ≥60 years have significantly higher mortality; pediatric patients appear to be relatively spared. Recent cancer treatment does not appear to significantly increase the risk of death.

11 November 2009 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JZJeffrey I. Zwicker
Jeffrey I. Zwicker
HLHoward A. Liebman
Howard A. Liebman
DNDonna Neuberg
Donna Neuberg
RLRomaric Lacroix
Romaric Lacroix
KBKenneth A. Bauer
Kenneth A. Bauer
BFBruce Furie
Bruce Furie
Purpose: Despite the strong association between malignant disease and thromboembolic disorders, the molecular and cellular basis of this relationship remains uncertain. We evaluated the hypothesis that tumor-derived tissue factor–bearing microparticles in plasma contribute to cancer-associated thrombosis. Experimental Design: We developed impedance-based flow cytometry to detect, quantitate, and size microparticles in platelet-poor plasma. We evaluated the number of tissue factor–bearing microparticles in a cohort of cancer patients of different histologies (N = 96) and conducted a case-control study of 30 cancer patients diagnosed with an acute venous thromboembolic event (VTE) compared with 60 cancer patients of similar age, stage, sex, and diagnosis without known VTE, as well as 22 patients with an idiopathic VTE. Results: Tissue factor–bearing microparticles were detected in patients with advanced malignancy, including two thirds of patients with pancreatic carcinoma. Elevated levels of tissue factor–bearing microparticles were associated VTE in cancer patients (adjusted odds ratio, 3.72; 95% confidence interval, 1.18-11.76; P = 0.01). In cancer patients without VTE, a retrospective analysis revealed a 1-year cumulative incidence of VTE of 34.8% in patients with tissue factor–bearing microparticles versus 0% in those without detectable tissue factor–bearing microparticles (Gray test P = 0.002).The median number of tissue factor–bearing microparticles in the cancer VTE cohort (7.1 × 104 microparticles/μL) was significantly greater than both the idiopathic VTE and cancer–no VTE groups (P = 0.002 and P = 0.03, respectively). Pancreatectomy in three patients eliminated or nearly eliminated these microparticles which coexpressed the epithelial tumor antigen, MUC-1. Conclusion: We conclude that tumor-derived tissue factor–bearing microparticles are associated with VTE in cancer patients and may be central to the pathogenesis of cancer-associated thrombosis. (Clin Cancer Res 2009;15(22):6830–40)

7 August 2012 in BMJ
Verified
Journal Article
Open access
PDF file
SMS. Mantha
S. Mantha
RKR. Karp
R. Karp
VRV. Raghavan
V. Raghavan
NTN. Terrin
N. Terrin
KBK. A. Bauer
K. A. Bauer
JZJ. I. Zwicker
J. I. Zwicker
Objectives To evaluate the risk of venous thromboembolic events associated with the use of progestin-only contraception and whether that risk differs with the mode of drug delivery (oral, intrauterine, or depot injection). Design Systematic review and meta-analysis of randomised controlled trials and observational studies. Data sources Pubmed, Embase, Cochrane Library, and reference lists of relevant reviews. Study selection Randomised controlled trials and case-control, cohort, and cross sectional studies with venous thromboembolic outcome for progestin-only contraception reported relative to a non-hormone comparator group. Data extraction Data were extracted by two independent investigators, and consensus for inclusion was reached after assessment by additional investigators. Results Among the 2022 unique references identified by all searches, eight observational studies fulfilled inclusion criteria. A total of 147 women across all studies were diagnosed with a venous thromboembolic event while taking progestin-only contraception, and the summary measure for the adjusted relative risk of a venous thromboembolic episode for users versus non-users of a progestin-only contraceptive was, based on the random effects model, 1.03 (95% CI 0.76 to 1.39). Subgroup analysis confirmed there was no association between venous thromboembolic risk and progestin-only pills (relative risk 0.90 (0.57 to 1.45)) or a progestin intrauterine device (0.61 (0.24 to 1.53)). The relative risk of a venous thromboembolic event for users of an injectable progestin versus non-users was 2.67 (1.29 to 5.53). Conclusions Published data assessing the risk of venous thromboembolism in women prescribed progestin-only contraception are limited. In this meta-analysis of eight observational studies, the use of progestin-only contraception was not associated with an increased risk of venous thromboembolism compared with non-users of hormonal contraception. The potential association between injectable progestins and thrombosis requires further study.

10 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
RPRushad Patell
Rushad Patell
TBThomas Bogue
Thomas Bogue
AKAnita Koshy
Anita Koshy
PBPoorva Bindal
Poorva Bindal
MMMwanasha Merrill
Mwanasha Merrill
JZJeffrey I. Zwicker
Jeffrey I. Zwicker
Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with a high incidence of thrombotic events during hospitalization; however, data examining rates of thrombosis after discharge are limited. We conducted a retrospective observational cohort study of discharged patients with confirmed COVID-19 not receiving anticoagulation. The cohort included 163 patients with median time from discharge to last recorded follow-up of 30 days (interquartile range [IQR], 17-46 days). The median duration of index hospitalization was 6 days (IQR, 3-12 days) and 26% required intensive care. The cumulative incidence of thrombosis (including arterial and venous events) at day 30 following discharge was 2.5% (95% confidence interval [CI], 0.8-7.6); the cumulative incidence of venous thromboembolism alone at day 30 postdischarge was 0.6% (95% CI, 0.1-4.6). The 30-day cumulative incidence of major hemorrhage was 0.7% (95% CI, 0.1-5.1) and of clinically relevant nonmajor bleeds was 2.9% (95% CI, 1.0-9.1). We conclude that the rates of thrombosis and hemorrhage appear to be similar following hospital discharge for COVID-19, emphasizing the need for randomized data to inform recommendations for universal postdischarge thromboprophylaxis.

7 December 2004 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JZJ. I. Zwicker
J. I. Zwicker
LUL. Uhl
L. Uhl
WHW.Y. Huang
W.Y. Huang
BSB. H. Shaz
B. H. Shaz
KBK. A. Bauer
K. A. Bauer

21 February 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
JZJeffrey I. Zwicker
Jeffrey I. Zwicker
BSBenjamin L. Schlechter
Benjamin L. Schlechter
JSJack D. Stopa
Jack D. Stopa
HLHoward A. Liebman
Howard A. Liebman
AAAnita Aggarwal
Anita Aggarwal
RFRobert Flaumenhaft
Robert Flaumenhaft
BACKGROUND. Protein disulfide isomerase (PDI) is a thiol isomerase secreted by vascular cells that is required for thrombus formation. Quercetin flavonoids inhibit PDI activity and block platelet accumulation and fibrin generation at the site of a vascular injury in mouse models, but the clinical effect of targeting extracellular PDI in humans has not been studied. METHODS. We conducted a multicenter phase II trial of sequential dosing cohorts to evaluate the efficacy of targeting PDI with isoquercetin to reduce hypercoagulability in cancer patients at high risk for thrombosis. Patients received isoquercetin at 500 mg (cohort A, n = 28) or 1000 mg (cohort B, n = 29) daily for 56 days, with laboratory assays performed at baseline and the end of the study, along with bilateral lower extremity compression ultrasound. The primary efficacy endpoint was a reduction in D-dimer, and the primary clinical endpoint included pulmonary embolism or proximal deep vein thrombosis. RESULTS. The administration of 1000 mg isoquercetin decreased D-dimer plasma concentrations by a median of –21.9% ( P = 0.0002). There were no primary VTE events or major hemorrhages observed in either cohort. Isoquercetin increased PDI inhibitory activity in plasma (37.0% in cohort A, n = 25, P < 0.001; 73.3% in cohort B, n = 22, P < 0.001, respectively). Corroborating the antithrombotic efficacy, we also observed a significant decrease in platelet-dependent thrombin generation (cohort A median decrease –31.1%, P = 0.007; cohort B median decrease –57.2%, P = 0.004) and circulating soluble P selectin at the 1000 mg isoquercetin dose (median decrease –57.9%, P < 0.0001). CONCLUSIONS. Isoquercetin targets extracellular PDI and improves markers of coagulation in advanced cancer patients. TRIAL REGISTRATION. Clinicaltrials.gov NCT02195232. FUNDING. Quercegen Pharmaceuticals; National Heart, Lung, and Blood Institute (NHLBI; U54HL112302, R35HL135775, and T32HL007917); and NHLBI Consortium Linking Oncology and Thrombosis (U01HL143365).